Holen Sie sich die Stockscreener-App
412.35
1.56%
-6.55
Vorhandelsmarkt:
422.50
10.15
+2.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$418.90
Offen:
$421.64
24-Stunden-Volumen:
623.27K
Relative Volume:
1.75
Marktkapitalisierung:
$9.16B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-16.42
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
-5.38%
1M Leistung:
-6.92%
6M Leistung:
+30.71%
1J Leistung:
+29.03%
1-Tages-Spanne:
$399.00
$430.50
1-Wochen-Bereich:
$393.61
$435.00
52-Wochen-Spanne:
$265.00
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
412.35 | 9.34B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal: Q3 Earnings Snapshot - MarketScreener
Madrigal Pharmaceuticals (NASDAQ: MDGL) reports $287.3M Q3 sales, up from $62.2M - Stock Titan
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikes2025 Market WrapUp & Daily Price Action Insights - newser.com
Visual analytics tools that track Madrigal Pharmaceuticals Inc. performanceJuly 2025 Setups & Daily Stock Trend Watchlist - newser.com
Can Madrigal Pharmaceuticals Inc. stock beat market expectations this quarterOptions Play & Weekly Chart Analysis and Guides - newser.com
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.Portfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockDay Trade & Weekly Return Optimization Plans - newser.com
Is Madrigal Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Chart based exit strategy for Madrigal Pharmaceuticals Inc.July 2025 Snapshot & Daily Profit Maximizing Tips - newser.com
Madrigal Pharmaceuticals (MDGL) Upgraded to Neutral by BofA on R - GuruFocus
Madrigal Pharmaceuticals upgraded at BofA on Rezdiffra uptake - Seeking Alpha
Why Madrigal Pharmaceuticals Inc. (YDO1) stock signals breakout potential2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
MDGL: B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals stock rating upgraded by BofA on strong launch - Investing.com Canada
BofA Upgrades Madrigal Pharmaceuticals to Neutral From Underperform, Price Target is $445 - MarketScreener
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsJuly 2025 Final Week & Reliable Momentum Entry Alerts - newser.com
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthEarnings Risk Summary & Free High Return Stock Watch Alerts - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownWeekly Risk Summary & Weekly Market Pulse Alerts - newser.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Madrigal Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 News Drivers & Daily Profit Maximizing Tips - newser.com
Can Madrigal Pharmaceuticals Inc. stock hit record highs againJuly 2025 EndofMonth & Pattern Based Trade Signal System - newser.com
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthJuly 2025 Institutional & Weekly High Potential Stock Alerts - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis tools2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
Madrigal Pharmaceuticals Inc. stock chart pattern explained2025 Technical Patterns & Risk Managed Investment Signals - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Research Analysts Offer Predictions for MDGL FY2025 Earnings - MarketBeat
Is it too late to sell Madrigal Pharmaceuticals Inc.July 2025 Analyst Calls & Intraday High Probability Setup Alerts - newser.com
Madrigal Pharmaceuticals, Inc. (MDGL) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
A Look at Madrigal Pharmaceuticals (MDGL) Valuation Following New Rezdiffra Data to Be Presented at AASLD 2025 - Sahm
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockExit Strategy Tips & Turn Market Volatility into Wealth - earlytimes.in
Madrigal Pharmaceuticals to Report Third-Quarter 2025 Results on November 4 - MSN
Emerald Mutual Fund Advisers Trust Boosts Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.Market Performance Summary & Risk Managed Trade Strategies - newser.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 5.4%Should You Sell? - MarketBeat
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):